United States Patent 7,199,098 (Copolymer-1) Scope, Claims, and US Patent Landscape

US Patent 7,199,098 is directed to copolymer-1 (Copaxone-like” random-sequence copolymer) compositions and manufacturing methods that rely on a controlled molecular-weight distribution (predominantly 2 to 20 kDa, with limited >40 kDa material) and non-uniformity in molecular weight and sequence, tied to use in multiple sclerosis (MS) and to lower toxicity at specified molecular-weight ranges.

What do the independent claims cover (scope)

Claim 1: Composition for treating multiple sclerosis with controlled MW distribution

Claim 1 is the primary composition claim. It requires four core elements:

Copolymer-1 composition defined as a mixture of copolymers made from amino-acid constituents:
- alanine, glutamic acid, lysine, tyrosine
Non-uniformity:
- “copolymer species… being non-uniform with respect to molecular weight and sequence”
Molecular-weight distribution constraints (molar fraction basis):
- >75% of copolymers have 2 kDa to 20 kDa
- <5% have >40 kDa
Therapeutic use:
- composition “is suitable for treating multiple sclerosis”

Scope implication: This claim is not tied to a single defined polymer chain length or a single repeating sequence. It covers a distribution of Copolymer-1 species as long as the MW distribution satisfies the numeric thresholds and the mixture composition is suitable for MS.

Claim 15: Process for preparing Copolymer-1 at specific average MW

Claim 15 covers a three-step manufacturing process that produces a Copolymer-1 composition with an average molecular weight of 4 to about 8.6 kDa.

Process elements:

Polymerization of:
- N-carboxyanhydride (NCA) of tyrosine
- NCA of alanine
- γ-benzyl glutamate
- trifluoroacetyllysine
Molar ratio:
- 1:5:2:4 (tyrosine:alanine:glutamate:lysine)
Deprotection to unprotected polypeptides
Isolation of Copolymer-1 composed of:
- glutamic acid, lysine, alanine, tyrosine
Target MW:
- “average molecular weight of 4 to about 8.6 kDa”

Scope implication: Claim 15’s protection is tightly anchored to:

starting materials and polymerization chemistry (NCAs, γ-benzyl glutamate, trifluoroacetyllysine),
the specific molar ratio 1:5:2:4,
deprotection and isolation steps,
and the resulting average MW window.

Claim 19: Composition with lower toxicity at MW below ~8.6 kDa

Claim 19 expands composition scope by adding a toxicity comparison:

Copolymer-1 mixture of the four amino acids
Average MW: 4 to about 8.6 kDa
Non-uniform molecular weight and sequence
“exhibits lower toxicity than” a Copolymer-1 composition with average MW > about 8.6 kDa

Scope implication: Claim 19 covers Copolymer-1 compositions in the specified MW range even if they do not strictly hit the detailed “>75% in 2–20 kDa and <5% >40 kDa” distribution thresholds of Claim 1, so long as the MW band and toxicity property are met.

How dependent claims narrow the product boundaries

Molecular-weight bands (average MW)

Dependent claims repeatedly specify average molecular weight targets that ladder within the overall Claim 1/15/17/19 framework:

Claim	MW requirement (average)	Notes
2	7000 Da ± 2000 Da	Broad “7 kDa” band
3	4 to 8.6 kDa	Matches the claim 15 window
4	6.25 to 8.4 kDa	Mid/high within band
5	4 to 8 kDa	Lower upper bound
6	7 to 8 kDa	Narrower sub-band
9	7000 Da ± 2000 Da	Tied to Claim 8
10	4 to 8.6 kDa	Tied to Claim 8
11	6.25 to 8.4 kDa	Tied to Claim 8
12	4 to 8 kDa	Tied to Claim 8
13	7 to 8 kDa	Tied to Claim 8
16	6.25 to 8.4 kDa	Process claim narrowing
18	6.25 to 8.4 kDa	Tied to Claim 17
20	6.25 to 8.4 kDa	Narrow sub-band for toxicity claim

Distribution-specific dependent claims

Claim 7 and Claim 14 reference an internal MW distribution figure, and Claim 8 imposes a “rare high MW tails” constraint:

Claim	Additional requirement	Scope effect
7	MW distribution “as depicted in FIG. 1” for avg MW 7.7 kDa	Requires that specific distribution profile
8	“less than 2.5%” of copolymers have MW >40 kDa	Tightens the <5% threshold of Claim 1
14	MW distribution “as depicted in FIG. 1” for avg MW 7.7 kDa	Mirrors Claim 7 but tied to Claim 8

Scope implication: In practice, Claim 1 establishes a distribution boundary (<5% >40 kDa). Claim 8 narrows it (<2.5% >40 kDa). Claims 7 and 14 attempt to lock the distribution shape via FIG. 1 for a specific mean (7.7 kDa). This can matter for infringement because many “generic-like” Copolymer-1 products differ in fraction of high MW tail and distribution shape even when average MW looks similar.

What do the manufacturing limitations imply for design-around

Claim 15/17 anchor method protection to a specific polymerization recipe and deprotection/isolation workflow. The chemistry constraint is relatively specific:

N-carboxyanhydride (NCA) forms are used for tyrosine and alanine
γ-benzyl glutamate is used as the glutamate precursor
trifluoroacetyllysine is used as the lysine precursor

And there is a molar ratio constraint of 1:5:2:4.

Design-around pressure point: A competitor aiming to avoid Claim 15/17 typically must alter either:

the precursor identities (avoid using the same NCA/derivatives),
or the stoichiometry ratio,
or the resulting average MW window,
or the claim’s isolating/deprotecting sequence (though deprotection is commonly required in polypeptide synthesis).

Even if a product ends up with the same MW distribution, method claims can be avoided if the manufacturing route differs materially from Claim 15’s recited steps.

How the “non-uniformity” feature affects breadth

Across Claims 1, 19, and (implicitly by dependence) the claims require mixtures that are:

“non-uniform with respect to molecular weight and sequence”

This matters because some Copolymer-1 preparations or research variants could attempt to create narrower distributions or more uniform sequence representations. By requiring non-uniformity, the claims:

do not target a single-defined polymer,
and instead cover realistic mixture distributions.

What is protected: compositions, properties, and uses

Property hooks used to expand/anchor enforceability

The patent uses multiple technical “hooks” that can be used in claim charting, lab testing, and infringement arguments:

MW distribution fraction constraints
- >75% in 2–20 kDa
- <5% above 40 kDa
- tightened to <2.5% above 40 kDa
Average MW ranges
- generally 4 to about 8.6 kDa
- with multiple narrower dependent subranges (notably 6.25 to 8.4 kDa and 7 to 8 kDa)
Distribution profile via FIG. 1
- distribution “as depicted” at avg 7.7 kDa
Toxicity comparative claim
- lower toxicity than MW > about 8.6 kDa

Therapeutic use hook

Claim 1 ties the composition to being “suitable for treating multiple sclerosis.” In US practice, use language can provide a second handle beyond composition-only coverage.

Claim-to-asset mapping (practical infringement posture)

A freedom-to-operate review typically breaks the analysis into:

product characterization (MW distribution, sequence non-uniformity, toxicity),
and manufacturing route (Claim 15/17 chemistry and ratio).

This patent’s likely strongest infringement path is for competitors whose Copolymer-1 product:

has an average MW in the 4 to 8.6 kDa band (and especially 6.25 to 8.4 kDa),
has a limited high-MW tail above 40 kDa,
and is marketed/used for MS.

The strongest product-characterization vulnerability is the combination of:

fraction thresholds at specific MW regions, plus
the “non-uniform” requirement, plus
potential reliance on FIG. 1 (if a distribution profile is distinctive).

The strongest manufacturing vulnerability is the specific NCA/precursor selection and 1:5:2:4 molar ratio in Claim 15/17.

US patent landscape context (what this patent likely sits among)

This patent is a “Copolymer-1 MW/specification” patent rather than a “new amino-acid monomers” patent. In practical landscapes, such assets typically cluster into families around:

controlling molecular weight distribution and tail fractions,
controlling mean MW to meet safety/PK targets,
and optionally tying manufacturing chemistry to the target MW range.

Likely landscape buckets

Original Copolymer-1 composition and use claims (broader earlier inventions)
Refinement patents controlling MW distribution and toxicity (like this one)
Manufacturing-method patents (precursor selection, polymerization and deprotection routes)
Formulation/device patents (buffers, delivery, particles), which are distinct from MW-only scope

Where this patent matters most: “evergreen” strategy around specification narrowing. Many Copolymer-1 product variants can have similar average MW but differ in:

distribution shape,
high MW tail percentage,
and the fraction in the 2–20 kDa region.

This patent is written to capture those differences through the distribution fraction limits and FIG-based profile references.

Competitive impact: which product specs are most “claim sensitive”

If a Copolymer-1 product targets the market with a specified MW average but does not control distribution, it can fall outside some dependent claims while still entering others.

Most claim-sensitive measurable targets

% molar fraction of chains 2–20 kDa
- must exceed 75% (Claim 1)
% molar fraction >40 kDa
- must be less than 5% (Claim 1)
- less than 2.5% (Claim 8)
Average MW
- 4 to 8.6 kDa (Claims 3, 15, 17, 19)
- 6.25 to 8.4 kDa (Claims 4, 16, 18, 20)
- 7 to 8 kDa (Claims 6, 13)
FIG. 1 distribution conformity
- specifically for average MW 7.7 kDa (Claims 7 and 14)
Toxicity comparison
- lower toxicity versus average MW >8.6 kDa (Claim 19)

Key Takeaways

US 7,199,098 protects Copolymer-1 mixtures for MS using molecular-weight distribution and mean MW specifications, plus a lower-toxicity property at average MW 4 to about 8.6 kDa (Claim 19).
The strongest composition scope (Claim 1) requires >75% of copolymers (molar fraction) in 2–20 kDa and <5% above 40 kDa, while the strongest tail tightening (Claim 8) uses <2.5% above 40 kDa.
The patent also protects a specific manufacturing route (Claim 15/17): polymerization from tyrosine and alanine NCA, γ-benzyl glutamate, and trifluoroacetyllysine at a 1:5:2:4 molar ratio, followed by deprotection and isolation, yielding average MW 4 to about 8.6 kDa.
Landscape impact is primarily in “specification evergreen” territory: competitors must control distribution shape and tail fractions, not just average MW, and method claims add further vulnerability where the route matches the enumerated precursor chemistry.

FAQs

1) What is the headline MW window in US 7,199,098?

The core window is average molecular weight 4 to about 8.6 kDa (Claims 3, 15, 17, 19), with repeated narrower subranges centered on 6.25 to 8.4 kDa.

2) Does the patent require control of the high MW tail?

Yes. Claim 1 requires <5% of copolymers above 40 kDa, and Claim 8 tightens that to <2.5% above 40 kDa, both on a molar fraction basis.

3) Is the claim limited to a single average molecular weight?

No. The patent includes multiple dependent claims with different average MW bands (for example 7000 Da ± 2000 Da; 4–8 kDa; 7–8 kDa; 6.25–8.4 kDa).

4) Are the polymers required to be sequence-uniform?

No. The claims require the copolymer species in the mixture to be non-uniform with respect to molecular weight and sequence, meaning the mixture need not be homogeneous.

5) What makes Claim 15 different from the composition claims?

Claim 15 is a process claim with specific precursor chemistry (NCA of tyrosine and alanine, γ-benzyl glutamate, trifluoroacetyllysine), a specific 1:5:2:4 molar ratio, and a resulting average MW window.

References

United States Patent No. 7,199,098. “Copolymer-1 compositions and methods for preparing the same.” (Claims 1-20 as provided).

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	0762888	⤷ Start Trial	90987	Luxembourg	⤷ Start Trial
European Patent Office	0762888	⤷ Start Trial	C300096	Netherlands	⤷ Start Trial
European Patent Office	0762888	⤷ Start Trial	C300251	Netherlands	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 7,199,098

Summary for Patent: 7,199,098